AiCure Stock
AiCure's intelligent medical assistant, IMA, leverages a visual recognition platform to monitor patient progress.
About AiCure Stock
AiCure's intelligent medical assistant, IMA, leverages a visual recognition platform to monitor patient progress. IMA provides visual dose confirmation, interactive patient support and engagement, and visual diagnostic capabilities. The platform has been validated to improve patient behavior in randomized controlled trials. In clinical research, AiCure is increasing the probability of trial success and introducing more objective clinical endpoints. In population health, AiCure is enabling intelligent decision-making and improving health outcomes. By 2020, there will be a one million nurse shortage in the US. AiCure is striving to help fill this gap. In clinical research, approximately one quarter of clinical trials fail due to a lack of patient oversight, contributing to over $40 billion in annual losses. AiCure is seeking to accelerate better medications into the market.
Funding History
| January 2016 | $12.3M |
|---|---|
| November 2017 | $15.0M |
Management
Chief Product Officer
Michelle Marlborough
Co-Founder & CSO
Laura Shafner
Co-Founder & CEO
Adam Hanina
Press
AiCure Raises $12.25 Million For Its Treatment Monitoring Technology
TechCrunch - Jan, 13 2016
Other Companies
EquityZen does not have an affiliation with, formal relationship with, or endorsement from AiCure or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
